Forward Science is a privately help MedTech company based in Houston, Texas. Forward Science was founded in 2012 by two biomedical engineers with the goal of innovating technology to change more lives. Being completely vertically integrated, Forward Science designs, develops, manufactures, commercializes and supports their products in-house, ensuring the highest quality of standards coupled with superior service. Forward Science has quickly evolved into the industry leader for providing oral healthcare products worldwide.
In addition to the Forward Science product portfolio, the company has expanded its capabilities to provide extensive resources for business growth including staffing solutions (Forward Staffing), innovative social media marketing (Forward Social), and contract manufacturing in their FDA certified facility (Forward Manufacturing).
Forward Science believes in leading and working with others to expand and improve public health and business expansion by supporting the diverse partnerships between communities and companies. Partners of Forward Science can al
OralID, Forward Science’s flagship product, is an award winning oral cancer screening device that allows clinicians to Shine Light. Change Lives.™ by identifying abnormalities that may not be seen under traditional white light examinations. Forward Science quickly expanded its product portfolio in efforts to provide clinicians with a complete program to battle the rising trends of oral cancer. In addition to the OralID device, Forward Science also offers diagnostic tests (CytID, PathID, hpvID, phID), and treatment options (SalivaMAX & SalivaCAINE).
SalivaMAX is Forward Science’s FDA Cleared prescription strength rinse for all ranges of xerostomia. Our latest product offering, SalivaCAINE has many of the ingredients as SalivaMAX with the added benefit of Benzocaine for temporary oral pain relief. SalivaMAX and SalivaCAINE are a perfect combination for anyone who is undergoing cancer treatment.
Company’s Keywords:
medical device, dental device, oral diagnostics, oral oncology
<46
<
<2012